Evidence map›Paper›PMID 30005601›Full record

ArticleBreast cancer research : BCR2018

Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer.

Aparna Shinde, Tomasz Wilmanski, Hao Chen, Dorothy Teegarden, Michael K Wendt

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Mitochondrial CaJournal of cellular physiology · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Aparna ShindePurdue University Center for Cancer Research, Purdue University, West Lafayette, IN, 47907, USA.
Tomasz WilmanskiPurdue University Center for Cancer Research, Purdue University, West Lafayette, IN, 47907, USA.
Hao ChenPurdue University Center for Cancer Research, Purdue University, West Lafayette, IN, 47907, USA.
Dorothy TeegardenPurdue University Center for Cancer Research, Purdue University, West Lafayette, IN, 47907, USA.
Michael K WendtPurdue University Center for Cancer Research, Purdue University, West Lafayette, IN, 47907, USA. mwendt@purdue.edu.ORCID 0000-0002-3665-7413
Purdue University West Lafayette · US

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI Andrea L Kasinski · 1985 to 2026
$43.4M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
Indiana Clinical and Translational Sciences InstituteTL1TR001107 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$2.0M
Overcoming metastatic resistance to ErbB-targeted therapiesR01CA207751 · NCI · PURDUE UNIVERSITY · PI WENDT, MICHAEL KEITH · 2017 to 2021
$1.7M
Interdisciplinary Cancer Prevention Research Internship ProgramR25CA128770 · NCI · PURDUE UNIVERSITY · PI TEEGARDEN, DOROTHY · 2008 to 2012
$1.5M
NCATS NIH HHS TL1 TR001107NCATS NIH HHS UL1 TR001108NCI NIH HHS P30 CA023168NCI NIH HHS R01 CA207751NCI NIH HHS R25 CA128770
6 · The paper itself

Abstract

backgroundOvercoming systemic dormancy and initiating secondary tumor grow under unique microenvironmental conditions is a major rate-limiting step in metastatic progression. Disseminated tumor cells encounter major changes in nutrient supplies and oxidative stresses compared to the primary tumor and must demonstrate significant metabolic plasticity to adapt to specific metastatic sites. Recent studies suggest that differential utilization of pyruvate sits as a critical node in determining the organotropism of metastatic breast cancer. Pyruvate carboxylase (PC) is key enzyme that converts pyruvate into oxaloacetate for utilization in gluconeogenesis and replenishment of the TCA cycle.

methodsPatient survival was analyzed with respect to gene copy number alterations and differential mRNA expression levels of PC. Expression of PC was analyzed in the MCF-10A, D2-HAN and the 4 T1 breast cancer progression series under in vitro and in vivo growth conditions. PC expression was depleted via shRNAs and the impact on in vitro cell growth, mammary fat pad tumor growth, and pulmonary and non-pulmonary metastasis was assessed by bioluminescent imaging. Changes in glycolytic capacity, oxygen consumption, and response to oxidative stress were quantified upon PC depletion.

resultsGenomic copy number increases in PC were observed in 16-30% of metastatic breast cancer patients. High expression of PC mRNA was associated with decreased patient survival in the MCTI and METABRIC patient datasets. Enhanced expression of PC was not recapitulated in breast cancer progression models when analyzed under glucose-rich in vitro culture conditions. In contrast, PC expression was dramatically enhanced upon glucose deprivation and in vivo in pulmonary metastases. Depletion of PC led to a dramatic decrease in 4 T1 pulmonary metastasis, but did not affect orthotopic primary tumor growth. Tail vein inoculations confirmed the role of PC in facilitating pulmonary, but not extrapulmonary tumor initiation. PC-depleted cells demonstrated a decrease in glycolytic capacity and oxygen consumption rates and an enhanced sensitivity to oxidative stress.

conclusionsOur studies indicate that PC is specifically required for the growth of breast cancer that has disseminated to the lungs. Overall, these findings point to the potential of targeting PC for the treatment of pulmonary metastatic breast cancer.

Indexed as

AnimalsBreast NeoplasmsCell Line, TumorCell ProliferationCitric Acid CycleFemaleGlucoseGlycolysisHumansLung NeoplasmsOxidative StressPyruvate CarboxylasePyruvic AcidTropismGlucosePyruvate CarboxylasePyruvic AcidBreast cancerGlycolysisHypoxiaMetabolismMetastasisOxidative stressPyruvate carboxylase

Identifiers

PMID30005601
PMCPMC6045837
OpenAlexW2951601616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.